Human Induced Pluripotent Stem Cells as a Screening Platform for Drug-Induced Vascular Toxicity
Open Access
- 10 March 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Abstract
Evaluation of potential vascular injury is an essential part of the safety study during pharmaceutical development. Vascular liability issues are important causes of drug termination during preclinical investigations. Currently, preclinical assessment of vascular toxicity primarily relies on the use of animal models. However, accumulating evidence indicates a significant discrepancy between animal toxicity and human toxicity, casting doubt on the clinical relevance of animal models for such safety studies. While the causes of this discrepancy are expected to be multifactorial, species differences are likely a key factor. Consequently, a human-based model is a desirable solution to this problem, which has been made possible by the advent of human induced pluripotent stem cells (iPSCs). In particular, recent advances in the field now allow the efficient generation of a variety of vascular cells (e.g., endothelial cells, smooth muscle cells, and pericytes) from iPSCs. Using these cells, different vascular models have been established, ranging from simple 2D cultures to highly sophisticated vascular organoids and microfluidic devices. Toxicity testing using these models can recapitulate key aspects of vascular pathology on molecular (e.g., secretion of proinflammatory cytokines), cellular (e.g., cell apoptosis), and in some cases, tissue (e.g., endothelium barrier dysfunction) levels. These encouraging data provide the rationale for continuing efforts in the exploration, optimization, and validation of the iPSC technology in vascular toxicology.Keywords
Funding Information
- American Heart Association
- National Institutes of Health (R01 HL146690 R01 HL141851 R01 HL141371 UH3 TR002588)
- Tobacco-Related Disease Research Program
- Burroughs Wellcome Fund
This publication has 112 references indexed in Scilit:
- Highly efficient induction and long-term maintenance of multipotent cardiovascular progenitors from human pluripotent stem cells under defined conditionsCell Research, 2013
- Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signalingProceedings of the National Academy of Sciences of the United States of America, 2012
- Generation of human vascular smooth muscle subtypes provides insight into embryological origin–dependent disease susceptibilityNature Biotechnology, 2012
- Market withdrawal of new molecular entities approved in the United States from 1980 to 2009Pharmacoepidemiology and Drug Safety, 2011
- Vascular Smooth Muscle Progenitor CellsCirculation Research, 2011
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese SubjectsNew England Journal of Medicine, 2010
- Cellular Heterogeneity: Do Differences Make a Difference?Cell, 2010
- Induction and Isolation of Vascular Cells From Human Induced Pluripotent Stem Cells—Brief ReportArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Cardiotoxicity induced by tyrosine kinase inhibitorsActa Oncologica, 2009
- Biomarkers and Mechanisms of Drug-Induced Vascular Injury in Non-RodentsToxicologic Pathology, 2006